Two experiments suggest new direction for diabetes

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - Two experimental treatments suggest new directions for treating diabetes, both using compounds already made by the body, researchers in the United States reported on Monday.

One of the two studies suggests that some current treatments for autoimmune diseases such as the bowel-cramping Crohn's disease may be taking the wrong approach and doing active harm in some patients.

The two reports, published in the Proceedings of the National Academy of Sciences, each aim to correct some of the things that go wrong to cause type-1 diabetes, which is caused when immune cells mistakenly destroy the cells in the pancreas that make insulin.

The International Diabetes Federation estimates that 230 million people globally have diabetes, and about 10 percent of these have type 1. Patients are usually diagnosed at a young age and must carefully measure blood sugar levels and take insulin for life. There is no cure.

Dr. Denise Faustman and colleagues at Massachusetts General Hospital and Harvard Medical School in Boston tested a cheap generic drug used to prevent tuberculosis, called bacillus Calmette-Guerin or BCG.

Faustman said BCG temporarily elevates levels of an immune system protein called tumor necrosis factor or TNF. Earlier studies had shown that raising TNF in mice can cure them of a condition resembling human diabetes.

"If you are a mouse, we have got you covered. But the ultimate goal is people," Faustman said.

'BAD' T-CELLS